Inhibrx Biosciences, Inc.
INBX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.16 | 0.06 | 0.08 | -0.07 |
| FCF Yield | -6.49% | -13.57% | -16.60% | -19.62% |
| EV / EBITDA | -11.10 | -1.68 | -2.66 | -1.66 |
| Quality | ||||
| ROIC | -23.52% | -15.62% | -21.14% | -35.25% |
| Gross Margin | 0.00% | 49.08% | 0.00% | -589.00% |
| Cash Conversion Ratio | 0.96 | 1.05 | 0.83 | 0.91 |
| Growth | ||||
| Revenue 3-Year CAGR | 47.08% | 32.71% | -46.14% | -54.88% |
| Free Cash Flow Growth | -12.96% | 16.60% | 17.88% | -43.27% |
| Safety | ||||
| Net Debt / EBITDA | 4.32 | 7.21 | 2.75 | 3.06 |
| Interest Coverage | 10.63 | -8.72 | -15.95 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -1,060.37 | -1,185.60 | -829.62 |